Brokerages have set a 1 year consensus price target of $5.50 for the company and are anticipating that the company will post ($0.45) EPS for the current quarter, according to Zacks. Zacks has also assigned Zosano Pharma Corporation an industry rank of 138 out of 265 based on the ratings given to related companies.
Zosano Pharma Corporation (NASDAQ:ZSAN) has received a consensus broker rating score of 2.00 (Buy) from the two brokers that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a hold recommendation and one has issued a strong buy recommendation on the company.
Separately, Zacks Investment Research upgraded shares of Zosano Pharma Corporation from a “sell” rating to a “hold” rating in a research note on Tuesday, October 25th.
Shares of Zosano Pharma Corporation (NASDAQ:ZSAN) opened at 1.20 on Wednesday. The firm has a 50-day moving average of $1.07 and a 200 day moving average of $0.93. The firm’s market cap is $20.18 million. Zosano Pharma Corporation has a 52 week low of $0.45 and a 52 week high of $2.83.
A hedge fund recently raised its stake in Zosano Pharma Corporation stock. Lombard Odier Asset Management USA Corp boosted its stake in Zosano Pharma Corporation (NASDAQ:ZSAN) by 66.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 795,722 shares of the company’s stock after buying an additional 318,450 shares during the period. Lombard Odier Asset Management USA Corp owned approximately 6.62% of Zosano Pharma Corporation worth $615,000 as of its most recent filing with the SEC. Institutional investors own 41.11% of the company’s stock.
About Zosano Pharma Corporation
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.
Get a free copy of the Zacks research report on Zosano Pharma Corporation (ZSAN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com